PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.
View Top Employees from PrimeVax Immuno-Oncology| Website | http://www.primevax.com |
| Revenue | $400000 |
| Employees | 6 (5 on RocketReach) |
| Founded | 2015 |
| Address | 400 Cypress Ave, South San Francisco, California 94080, US |
| Phone | (714) 585-7485 |
| Industry | Business Services, Biotechnology Research, Pharmaceutical, Health Care |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular PrimeVax Immuno-Oncology employee's phone or email?
PrimeVax Immuno-Oncology Questions
The PrimeVax Immuno-Oncology annual revenue was $400000 in 2024.
5 people are employed at PrimeVax Immuno-Oncology.
PrimeVax Immuno-Oncology is based in South San Francisco, California.
The NAICS codes for PrimeVax Immuno-Oncology are [5417, 541, 54, 541714, 54171].
The SIC codes for PrimeVax Immuno-Oncology are [87, 873].
Top PrimeVax Immuno-Oncology Employees
-
View
Andrew Zloza
Senior Director of Translational Science at PrimeVax Immuno-Oncology
Chicago, Illinois, United States5+5+ -
ViewMargaret Murray
Strategy and Operations Analyst at PrimeVax Immuno-Oncology
Fort Worth, Texas, United States2
Related Companies
